- Published at
- by gurufocus.com
neutral
neutral
XORTX Announces Update for Discussion with the FDA
â— Type B Meeting Discussion to Accelerate XRx-026 for Gout to NDA â— CALGARY, Alberta, March 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX